// App-Quantinova.ai

e16057 : Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program.

Researchers

Presenter

  • Sylvie Rottey

Principal Investigators

  • Fransien Van Hende

  • Jean-Pascal H. Machiels

  • Dirk L. Schrijvers

  • Els Grieta Everaert

  • Lionel A. D'Hondt

  • Patrick Werbrouck

  • Joanna Vermeij

  • Jeroen Mebis

  • Marylene Clausse

  • Filip Van Aelst

  • Wim Wynendaele

  • Thierry Gil

  • Peter Schatteman

  • Bertrand Filleul

  • Denis C. C. Schallier

  • Nicolaas Lumen

  • Gino Pelgrims

  • Wim Demey

Medical Centers

  • AZ Groeninge, Kortrijk, Belgium

  • AZ Jessa, Hasselt, Belgium

  • ZNA Middelheim, Antwerp, Belgium

  • Universitair Ziekenhuis, Brussels, Belgium

  • St Luc Bouge, Namur, Belgium

  • Cliniques Universitaires UCL de Mont-Godinne, Namur, Belgium

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Institut Roi Albert II, Cliniques universitaires St-Luc, UCL, Brussels, Belgium

  • OLV Aalst, Aalst, Belgium

  • AZ Nikolaas, Sint-Niklaas, BelgiumAZ Turnhout, Turnhout, BelgiumGhent University Hospital, Ghent, Belgium

  • ZNA Campus Jan Palfijn Middelheim, Merksem, Belgium

  • Medische Oncologie, Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium

  • AZ Delta, Roeselare, Belgium

  • AZ KLINA, Kalmthout, Belgium

  • Hopital de Jolimont, Haine St Paul, Belgium

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

Locations

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Solid malignancies

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved